Regeneron Pharmaceuticals, Inc. $REGN Stock Position Boosted by New England Research & Management Inc.

Posted by Brenda Bartman on Oct 17th, 2026

New England Research & Management Inc. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 20.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 4,185 shares of the biopharmaceutical company’s stock after buying an additional 710 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.2% of New England Research & Management Inc.’s holdings, making the stock its 23rd largest holding. New England Research & Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,173,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of REGN. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after buying an additional 170,210 shares during the period. Invesco Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 7.2% in the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after buying an additional 106,632 shares during the period. Bank of America Corp DE boosted its holdings in shares of Regeneron Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after buying an additional 101,469 shares during the period. Finally, Amundi increased its position in shares of Regeneron Pharmaceuticals by 0.4% during the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after acquiring an additional 3,742 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Sanford C. Bernstein boosted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a research report on Friday, August 14th. Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Evercore upped their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $845.21.

View Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Down 0.7%

REGN stock traded down $5.60 during midday trading on Friday, hitting $790.74. The company’s stock had a trading volume of 653,510 shares, compared to its average volume of 800,313. The company’s fifty day moving average price is $791.72 and its 200 day moving average price is $721.78. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a twelve month low of $566.11 and a twelve month high of $859.34. The stock has a market capitalization of $81.41 billion, a P/E ratio of 19.54, a PEG ratio of 1.38 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $12.81 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

Insider Buying and Selling

In related news, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,093 shares of company stock worth $6,506,845. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.